NIQ Expands Product Intelligence Across Western Europe, Strengthening the Foundation for AI-Driven Commerce

NIQ Expands Product Intelligence Across Western Europe, Strengthening the Foundation for AI-Driven Commerce

Enhanced capabilities connect product attributes with market performance, helping brands and retailers understand shopper choice today and prepare for AI-mediated discovery 

LONDON–(BUSINESS WIRE)–NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of NIQ Product Insights (NPI) across Western Europe, strengthening its Product Intelligence portfolio to help brands and retailers better understand what drives shopper choice and category growth. The expansion brings enhanced product intelligence capabilities to Austria, Belgium, Italy, Netherlands, Portugal, Spain and Switzerland, building on existing availability in France, Germany, Ireland, and the United Kingdom. 

As shoppers, and increasingly the digital and AI-powered tools that guide them, evaluate products against specific health, wellness, sustainability, and ingredient preferences, product attributes are becoming an increasingly important part of commerce’s intelligence infrastructure. Brands and retailers need more than traditional market measurement to understand which attributes influence selection and  drives growth. NPI connects those attributes with real-world sales performance. 

NPI combines trusted product attributes, including ingredients, claims, certifications, nutrients, and functional benefits, with NIQ market measurement data. It helps clients answer two critical questions: what products match a shopper’s needs, and which attributes actually drive purchase and growth. That intelligence supports decisions across innovation, pricing, and assortment today while creating a stronger foundation as product discovery and selection become increasingly AI-mediated.

Why NPI matters to brands and retailers 

As consumer expectations evolve, product attributes are becoming a key driver of purchase decisions and category growth. NIQ analysis* shows that: 

  • 41% of Western European consumers are willing to pay more for products with elevated ingredients or formulations. 

  • 39% of Western European consumers are willing to pay more for ingredient and supply chain transparency. 

  • Specific product benefits are significantly outpacing broader category growth. In Germany, shampoo products with a stated “Gentle Formula” benefit grew +48%, compared with growth of less than 1% for the total shampoo category. 

  • High-growth attributes can also be associated with significant price premiums. In UK skin cleansing, products with a stated hyaluronic acid claim grew +61% and averaged £15.87/kg—more than three times the category average price of £5.04/kg. 

  • NPI helps brands connect product attributes directly to purchasing behaviour, helping close the gap between what consumers say matters and what actually drives sales. 

“As shoppers, and increasingly AI-powered shopping tools, evaluate products against more specific needs and preferences, Product Intelligence is becoming essential commerce infrastructure,,” said Emilie Darolles, President, Western Europe. “NIQ Product Insights helps our clients connect trusted product attributes with market performance so they can innovate faster, optimize their product strategies, and make more confident commercial decisions. It is an important part of our broader Product Intelligence strategy as we continue investing in the future of AI-driven commerce.” 

The Western Europe expansion builds on NIQ’s continued investment in Product Intelligence, advanced analytics, and consumer intelligence, following successful NPI launches in Canada, France, Germany, Ireland, and the United Kingdom. As part of NIQ’s broader Connected Content strategy and The Full View™, NIQ’s Product Intelligence portfolio brings together trusted product content, structured product data, contextual intelligence, and market measurement to help brands and retailers better understand how products are represented, discovered, interpreted, and selected across modern commerce environments. 

Combined with NIQ’s continued investment in next-generation AI capabilities, Product Intelligence helps clients transform trusted product information into actionable intelligence. By connecting trusted product attributes with market performance and shopper behaviour, clients can identify emerging trends earlier, better understand their competitive landscape, accelerate innovation, and make smarter decisions across pricing, assortment, and go-to-market strategy.

Notes to Editors 

*Data referenced in this release is drawn from NIQ Consumer Outlook research, NIQ Global Health & Wellness Survey 2025, NIQ Consumer Panel Services, NIQ Retail Measurement Services (Scantrack), and NIQ Product Insights data across Western Europe. Analysis reflects the latest available data for each market and metric, as indicated in the underlying research. 

Frequently Asked Questions 

Q: What is NIQ Product Insights (NPI)? 

A: NIQ Product Insights (NPI) is a core capability within NIQ’s Product Intelligence portfolio, connecting detailed product attributes—such as ingredients, claims, certifications, nutrients, and functional benefits—with NIQ’s market measurement data. This enables brands and retailers to understand not just what products are selling, but which product attributes are driving growth and shopper choice. 

Q: Why is NIQ expanding NPI across Western Europe? 

A: As shoppers increasingly make purchasing decisions based on health, sustainability, ingredient transparency, and product benefits, brands and retailers need more granular insight into what drives performance. Expanding NPI across Western Europe provides clients with a consistent view of product attributes and market performance across key regional markets. 

Q: What makes NPI different from traditional market measurement? 

A: Traditional market measurement shows what products are selling and how categories are performing. NPI adds a layer of product intelligence that helps explain why products are growing or declining by linking attributes such as ingredients, claims, certifications, and nutrients directly to sales performance. 

Q: How does NPI help close the “say-do gap”? 

A: Many companies rely on surveys to understand consumer preferences and attitudes. NPI complements these insights by connecting product attributes to actual purchasing behaviour, helping clients understand whether the attributes consumers say they value are truly influencing real-world buying decisions. 

Q: Who can benefit from NPI? 

A: NPI is designed for manufacturers, retailers, ingredient suppliers, packaging companies, category managers, innovation teams, and insights professionals looking to better understand the drivers of growth, shopper choice, and category performance. 

Q: What types of decisions can NPI support? 

A: NPI helps clients make more informed decisions across innovation, product development, assortment strategy, pricing, promotion, category management, shopper marketing, and retail media by revealing which attributes are resonating most with consumers. 

Q: What types of attributes are included in NPI? 

A: NPI captures hundreds of product attributes across ingredients, claims, certifications, nutrients, sustainability indicators, and functional benefits. Attributes include both stated attributes (visible on-pack claims and certifications) and qualified attributes derived from ingredient and nutrition information. 

Q: How is NPI different from product claims data? 

A: While product claims are an important part of NPI, the solution goes further by combining claims, certifications, ingredients, nutrients, and other product characteristics with market performance data. This enables clients to understand the commercial impact of product attributes rather than simply identifying their presence. 

Q: Where is NPI available? 

A: NPI is currently available across multiple markets globally, including Canada, France, Germany, Ireland, the United Kingdom, and now additional Western European markets including Belgium, Netherlands, Austria, Switzerland, Portugal, Spain, and Italy. 

Q: How does NPI support NIQ’s Full View™ strategy? 

A: NPI strengthens NIQ’s Full View™ by connecting product intelligence with market measurement and shopper behaviour. This gives clients a more complete understanding of what consumers are buying, why they are buying it, and which attributes are driving growth across markets and categories. 

Q: Is NPI part of NIQ’s broader innovation roadmap? 

A: Yes. NPI is a strategic investment that expands NIQ’s ability to help clients understand evolving shopper needs, identify emerging trends, and make more confident decisions. NIQ continues to invest in expanding NPI coverage, capabilities, and market availability globally. 

About NIQ 

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™. 

For more information, please visit: www.niq.com 

Forward-Looking Statements

This press release contains forward-looking statements regarding NIQ’s Product Intelligence strategy, the anticipated expansion and capabilities of NIQ Product Insights (NPI), continued investment in AI-driven commerce, and the expected evolution of product discovery and shopper decision-making. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as “will,” “expects,” “anticipates,” “becoming,” “believes,” and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, regulatory developments, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Retail Online Retail Data Analytics Professional Services

MEDIA:

Logo
Logo

MAYFAIR GOLD ADVANCES EXPLORATION TARGETS AND PROJECT GEOLOGY AT FENN-GIB

PR Newswire

TORONTO, Sept. 8, 2026 /PRNewswire/ — Mayfair Gold Corp. (“Mayfair”, “Mayfair Gold”, or the “Company”) (TSXV: MFG) (NYSE American: MINE) is pleased to report on its summer exploration program progress and mine geology advancement to further its operational readiness program.

2026 Summer Geology Program Highlights:

  • Advanced South Block targets toward drill-ready status
  • Mapped more than 95% of known outcrops and collected 127 grab samples
  • Completed 23 condemnation holes totalling 6,184 metres, confirming the site General Arrangement
  • Advanced the integrated 3D geological and multi-element geochemical model

Adree DeLazzer, P.Geo, Vice President, Exploration, commented, “this season’s work has strengthened our geological understanding of the North and South blocks and advanced priority targets on the South Block toward planned drilling in early 2027. Integrating our mapping, sampling and structural interpretation will help us refine these targets and focus the next phase of exploration. In parallel, we are developing an integrated geological and geochemical model at Fenn-Gib to better understand the deposit and guide exploration across the broader property. We are encouraged by the South Block’s potential and look forward to testing the targets developed through this work.

2026 Exploration Program

The 2026 exploration program focused on advancing the geological understanding of the North and South blocks (see figures 1 and 2 below) through systematic geological mapping, prospecting, sampling, and compilation of historical data. Over 95% of known outcrops across both blocks were reviewed, mapped and selectively sampled, providing extensive coverage of the property and adding significantly to the geological dataset available for ongoing interpretation and targeting.

A total of 127 grab samples were collected across the North and South blocks, including selected samples for gold assay and multi-element geochemical analysis. Geological and structural observations recorded during fieldwork focused on documenting structural features, lithology, alteration, and mineralization. The results of this work are being integrated with existing historical datasets to build a more complete understanding of the property.

A structural targeting program is also underway and has identified a number of areas for further evaluation. These targets are being integrated with the results of the summer mapping and sampling program to help refine areas for potential follow-up geological, geochemical, and geophysical work.

The Company is currently finalizing plans for its fall and winter exploration programs.

Figure 1: North Block

Figure 2: South Block

Infrastructure Condemnation Drilling Program

Mayfair has completed its 2026 condemnation drilling program, comprising 23 drill holes totalling 6,184 metres, including two redrills. The program was designed to test the proposed locations of key project infrastructure identified in the 2026 Pre-Feasibility Study Technical Report. The drilling results confirm that the tested locations remain suitable for the planned infrastructure, and no changes to the current site layout are required.

Figure 3: Map of Condemnation Drilling Program


Condemnation Program Assay Highlights


Hole-ID


From

(Meters)


To

(Meters)


Length*

(Meters)


Au g/t


Lithology


FGN26-031

51.00

67.75

16.75

0.52

AMV

and

260.00

261.25

1.25

1.28

MV


FGN26-033

178.30

181.00

2.70

2.84

AMV


including


179.70


181.00


1.30


5.41


MV


FGN26-035

87.00

90.00

3.00

0.66

SED

and

296.50

298.00

1.50

0.51

SED


FGN26-036

49.00

50.50

1.50

3.27

SED


FGN26-037

180.90

184.00

3.10

0.64

ASED


including


183.00


184.00


1.00


1.05


ASED

and

271.00

275.00

4.00

0.62

ASED


FGN26-038

198.30

202.50

4.20

1.58

SED


including


201.00


202.50


1.50


3.50


SED


FGN26-039

91.50

92.60

1.10

0.73

SED


FGN26-040

82.50

84.00

1.50

4.45

SED


FGN26-041a

238.50

240.00

1.50

3.64

SED

and

263.00

264.50

1.50

1.11

SED


FGN26-043

224.00

225.50

1.50

0.60

SED


FGN26-048

163.00

164.50

1.50

0.50

SED

and

167.50

169.00

1.50

0.67

SED


FGN26-050

278.00

279.50

1.50

1.14

SED

and

296.00

297.50

1.50

0.52

SED


* True Thickness for condemnation drilling is unknown.


Lithology codes: “MV” mafic volcanics; “SED” sediments; denominator “A” denotes altered nature

 


Condemnation Drilling – Collar Information


Hole ID


Easting


Northing


Elevation

 Length
(Meter)


Azimuth


Dip

FGN26-030

557334

5375791

326

300

5

-50

FGN26-031

557865

5376070

316

300

340

-50

FGN26-032

558548

5376155

314

300

25

-50

FGN26-033

559084

5375595

312

300

25

-50

FGN26-034

559125

5374660

314

53

0

-50

FGN26-034a

559122

5374662

312

300

0

-50

FGN26-035

558729

5374163

312

300

0

-50

FGN26-036

558739

5374641

313

300

25

-50

FGN26-037

558291

5374722

314

300

0

-50

FGN26-038

557811

5374182

312

301

0

-50

FGN26-039

557799

5374738

315

300

0

-50

FGN26-040

558273

5374186

312

300

0

-50

FGN26-041

557393

5375141

317

72

335

-50

FGN26-041a

557393

5375141

317

300

335

-50

FGN26-042

557397

5374623

316

300

335

-50

FGN26-043

557170

5373775

310

300

335

-50

FGN26-044

559121

5374225

312

187

0

-50

FGN26-045

556964

5374878

317

300

335

-50

FGN26-046

556820

5374402

316

300

335

-50

FGN26-047

556717

5373786

310

300

335

-50

FGN26-048

556284

5374488

316

171

335

-50

FGN26-049

556744

5375186

323

300

335

-50

FGN26-050

556283

5375246

317

300

335

-50


*Coordinates reported in NAD83 Zn 17N

Mine Geology and Geochemical Modelling

Efforts are underway to build a comprehensive 3D model integrating geology and a multi-element database. To date, over 900 inductively coupled plasma mass spectrometry assays (ICP-MS) have been taken in and around the main Fenn-Gib deposit. Mayfair is continuing to expand the database and model key elements to strengthen the geo-metallurgy model. The final product will also serve in vectoring pathfinder elements to support exploration efforts on the property scale.

Acid-based accounting assays (ABA) are also being included to further support and strengthen the various environmental baseline studies.

Finally, the previously reported grade control program yielded favorable results (see news release dated June 18, 2026). Mayfair is currently considering options to capitalise on those results and potentially do targeted infill drilling to pursue that program.

Quality Assurance and Quality Control

Mayfair Gold maintains a Quality Assurance/Quality Control (QA/QC) program aligned with NI 43-101 requirements and industry best practices. NQ size surface drilling was carried out by Black Diamond Drilling of Matheson, Ontario, and by Wiijiiwaagan Drilling Limited Partnerships of Haileybury, Ontario, under the supervision of Mayfair Gold’s exploration team. The drill program includes detailed geological logging and systematic sampling of drill core at Mayfair’s secure facility in Matheson, Ontario.

Drill core selected for analysis was cut longitudinally using a diamond‑blade saw. One half of the core was retained in the core box for reference, and the other half was bagged, sealed, and prepared for shipment. Analytical work was completed by Swastika Laboratories Ltd. in Swastika, Ontario. Swastika Laboratories is independent of Mayfair Gold and accredited by the Canadian Association for Laboratory Accreditation Inc. (CALA) and meets the ISO/IEC 17025 standards for gold analysis by fire assay with gravimetric finish and fire assay with flame atomic absorption spectroscopy (FAAS) finish.

Samples were delivered directly to Swastika Laboratories by Mayfair personnel. Samples are crushed to minimum 80% passing 1,700 μm. Samples are then split to obtain a 300–500 g sample using a rotary divider. 300–500 g samples are pulverized to minimum 85% passing 74 μm. Gold assays were completed using a 30‑gram fire assay with FAAS finish. Samples returning gold grades greater than 10 g/t were re‑assayed using a 30‑gram fire assay with gravimetric finish. As part of Mayfair’s QA/QC protocol, one certified reference material (CRM), one coarse blank, and one coarse duplicate sample were inserted into the sequence of every 25 samples. Routine third‑party check assays are also performed.

True thickness for condemnation drilling is unknown.

Mayfair Gold is a Canadian development-stage gold company focused on advancing the 100% controlled Fenn-Gib Project in the Timmins region of Northern Ontario. Fenn-Gib hosts a 4.3 million ounce indicated mineral resource of gold (181.3Mt at an average grade of 0.74 g/t) and the expected strategy outlined in the 2026 Pre-Feasibility Study (the “PFS”)1 is to develop the project under the provincial permitting process, targeting the higher-grade 1 million ounce probable mineral reserve (25.1Mt at an average grade of 1.29g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also outlines the potential to develop Fenn-Gib into a new Canadian gold producer, with initial development capital of C$450 million, a base-case payback period of 2.7 years, and cumulative free cash flow2 of US$896 million over the first six years of production based on a US$3,100/oz gold price. The Company is advancing permitting activities, detailed engineering, and stakeholder engagement with the goal of starting construction in 2028 with initial production in 2030. The company also remains focused on exploration around the broader land package with the goal of enhancing mineral resource scale and growth opportunities.

The geological information contained in this news release has been reviewed and approved by Adree DeLazzer, P.Geo., Vice President, Exploration of Mayfair, and the remaining technical information has been reviewed and approved by Drew Anwyll, P.Eng., Chief Executive Officer of Mayfair. Ms. DeLazzer and Mr. Anwyll are Qualified Persons as defined by National Instrument 43-101.

_________________________



1
 Please refer to the technical report entitled “Fenn-Gib Gold Project NI 43-101 Technical Report and pre-Feasibility Study” dated effective December 19, 2025 available on SEDAR+ at www.sedarplus.ca for further details.



2
 Free cash flow does not have a standardized meaning and may not be comparable to similar measures presented by other issuers, referred to as non-GAAP financial measures. As the Corporation is not in production, the Corporation does not have historical non-GAAP financial measures nor historical comparable measures under IFRS, and therefore the foregoing prospective non-GAAP financial measures may not be reconciled to the nearest comparable measures under IFRS.

Cautionary Note Regarding Forward-Looking Information

This news release contains certain forward-looking information within the meaning of applicable Canadian securities legislation and forward-looking statements within the meaning of applicable United States securities legislation (collectively, “forward-looking information”). The use of the words “will” and “expected” and similar expressions is intended to identify forward-looking information. Forward-looking information in this news release includes, but is not limited to, the expected strategy to develop the project under the provincial permitting process, de-risking of early years’ high-grade feed and cash flow profile, the potential to bring forward higher-grade production, targeting the higher-grade mineral reserve, building and operating the Fenn-Gib Project and all disclosure related to the PFS, including commencement of construction and production. Although Mayfair Gold believes that the expectations reflected in such forward-looking information is reasonable, readers are cautioned that actual results may vary from the forward-looking information. The Company has based the forward-looking information on the Company’s current expectations and assumptions about future events. This information also involves known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including the risks, uncertainties, and other factors identified in the annual information form and Form 40-F of the Company for the year ended December 31, 2025, available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov, respectively. Furthermore, the forward-looking information contained in this news release is as at the date of this news release, and Mayfair does not undertake any obligation to publicly update or revise any of this forward-looking information except as may be required by applicable securities laws. 

Neither the TSX Venture Exchange (“TSXV”) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Mayfair Gold Corp Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mayfair-gold-advances-exploration-targets-and-project-geology-at-fenn-gib-302871837.html

SOURCE Mayfair Gold Corp.

Canaan Inc. Reports Unaudited Second Quarter 2026 Financial Results

PR Newswire

Reached a record 1,915 BTC and 3,952 ETHcryptocurrency treasury

[1]


Mined 243 bitcoins in the Second Quarter 2026

Repurchased approximately 16.4 million ADSs for an Aggregate of US$7.4 million as of
September 8, 2026

SINGAPORE, Sept. 8, 2026 /PRNewswire/ — Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), an innovator in compute and energy infrastructure, today announced its unaudited financial results for the three months ended June 30, 2026.

Second Quarter 2026 Operating and Financial Highlights


Metrics


Second Quarter 2026


Key takeaways


BTC produced

243 BTC

Continued mining
output



Crypto treasury

1,915.50 BTC / 3,951.70
ETH

Record-high
treasury


Installed mining computing
power (Non-JV)

10.05 EH/s

Up 23.3% YoY


All-in power cost

~US$0.043 /kWh

Competitive mining
cost base


ABC Projects

49% interest / 4.85 EH/s
installed hashrate by the
end of July 2026

Steady fleet
upgrade


Share repurchased under
current share repurchase
program

16.4 million ADSs /

US$7.4 million

Disciplined capital
allocation

Nangeng Zhang, chairman, and chief executive officer of Canaan, commented, “Q2 2026 presented a difficult period for bitcoin mining, as renewed bitcoin price pressure, weaker mining economics, and seasonal power constraints weighed on equipment demand and profitability. Our team responded by staying close to customers, matching production to demand, and protecting liquidity. We generated US$31.9 million in total revenue with 2.5 EH/s of computing power sold during the second quarter. Our mining operations produced 243 bitcoins and continued to generate positive cash contribution before depreciation, supported by competitive power economics, while our digital asset treasury reached a record 1,915 BTC and 3,952 ETH at quarter-end. Beyond revenue generation, we kept our inventory lean, tightened spending and cash-flow management, and further streamlined our organization.

“Despite the quarter’s market headwinds, we focused on building the capabilities that we believe are necessary for Canaan’s next phase. Together with our partner, we advanced the fleet upgrade at Project ABC, where installed hashrate reached 4.85 EH/s by the end of July. We will continue to explore cost-advantaged sites that can support efficient deployment and cash generation, while advancing collaboration around compute-to-heat reuse applications. On the product side, we kept optimizing the A16 series, focusing on cost-effective air-cooled models and high-temperature water-cooled models, and developed new Avalon Home products for household heating applications, with mass-production preparations underway for the winter heating season. In parallel, we continued advancing our efforts on long-term power resources in North America with further progress. We will provide updates when we reach an appropriate stage for disclosure. As we expand beyond mining equipment and operations into compute-plus-energy infrastructure, these initiatives are designed to improve fleet efficiency, broaden our operating flexibility, and strengthen our foundation for long-term value creation as the industry evolves.”

Jin “James” Cheng, chief financial officer of Canaan, stated, “We navigated a demanding Q2 market and generated US$31.9 million in total revenue. Product revenue was US$13.6 million, reflecting softer demand for mining rigs and a lower average selling price for computing power, while mining revenue recorded US$17.7 million amidst bitcoin price pressure and seasonal curtailments. We kept mining-machine production costs relatively stable and held our all-in power cost at a competitive level of around US$0.04/kWh across our mining operations. Nevertheless, our reported results were also affected by several non-cash items, including a US$25.3 million inventory write-down, prepayment write-down, and provision for reserve for inventory purchase commitments, a US$9.2 million impairment of property and equipment, and a US$18.2 million loss of fair value change in cryptocurrency, all of which resulted from a decrease in cryptocurrency prices during the second quarter. These accounting charges weighed on our bottom line but did not alter our focus on cost control, liquidity, and operational efficiency.

“As we enter the second half of 2026, we intend to maintain disciplined inventory levels, preserve financial flexibility, and direct resources toward securing power capacity for our compute-energy infrastructure strategy. We are also applying a more active capital-allocation framework to monetize a portion of our digital asset treasury to fund stock repurchases under the existing program. The Company has deployed an aggregate US$7.4 million to repurchase 16.4 million ADSs under the current share repurchase plan as of today, alongside management’s continued share purchases using their personal funds. We believe the Company’s current equity valuation understates the combination of our digital asset treasury, cash liquidity, and our mining operations, which continue to generate bitcoin rewards. Repurchasing shares represents an attractive use of capital alongside the exploration of lower-cost power and infrastructure. We will continue balancing near-term resilience with opportunities that can strengthen per-share value and support Canaan’s long-term development.”

Note 1: Defined as the total number of bitcoins and other cryptocurrencies owned by the Company on its Balance Sheet, including any bitcoins receivable, excluding bitcoins that the Company has received as customer deposits.

Second Quarter 2026 Financial Results

Total revenues in the second quarter of 2026 were US$31.9 million, compared to US$62.7 million in the first quarter of 2026 and US$100.2 million in the same period of 2025. Total revenues consisted of US$13.6 million in products revenue, US$17.7 million in mining revenue, and US$0.6 million in other revenues.

Products revenue in the second quarter of 2026 was US$13.6 million, compared to US$42.9 million in the first quarter of 2026 and US$71.9 million in the same period of 2025. The sequential and year-over-year decreases were mainly due to the decreased computing power sold and average selling price, resulting from a tightening of overall market demand led by the decline in the bitcoin price.

Mining revenue in the second quarter of 2026 was US$17.7 million, compared to US$19.1 million in the first quarter of 2026 and US$28.1 million in the same period of 2025. The sequential and year-over-year decreases were mainly due to the decrease in the average bitcoin price.

Cost of revenues in the second quarter of 2026 was US$61.2 million, compared to US$85.6 million in the first quarter of 2026 and US$90.9 million in the same period of 2025.

Products costs in the second quarter of 2026 were US$40.3 million, compared to US$62.4 million in the first quarter of 2026 and US$58.8 million in the same period of 2025. The sequential and year-over-year decreases were consistent with the decrease in computing power sold. The inventory write-down, prepayment write-down, and provision for reserve for inventory purchase commitments accrued for this quarter were US$25.3 million, compared to the inventory write-down, prepayment write-down, and provision for reserve for inventory purchase commitments amounting to US$24.5 million for the first quarter of 2026 and the inventory write-down of US$1.0 million for the same period of 2025. Products costs consist of direct production costs of mining machines, and indirect costs related to production, as well as inventory write-down, prepayment write-down, and provision for reserve for inventory purchase commitments.

Mining costs in the second quarter of 2026 were US$20.4 million, compared to US$22.7 million in the first quarter of 2026 and US$32.0 million in the same period of 2025. Mining costs herein consist of direct production costs of mining operations, including electricity and hosting, as well as depreciation of deployed mining machines. The sequential and year-over-year decreases were mainly due to the decreased energized computing power. The depreciation in this quarter for deployed mining machines was US$6.3 million, compared to US$5.8 million in the first quarter of 2026 and US$10.5 million in the same period of 2025.

Gross loss in the second quarter of 2026 was US$29.3 million, compared to a gross loss of US$22.9 million in the first quarter of 2026 and a gross profit of US$9.3 thousand in the same period of 2025.

Total operating expenses in the second quarter of 2026 were US$40.1 million, compared to US$31.4 million in the first quarter of 2026 and US$36.4 million in the same period of 2025.

Research and development expenses in the second quarter of 2026 were US$14.9 million, compared to US$15.4 million in the first quarter of 2026 and US$16.4 million in the same period of 2025. The sequential decrease was mainly due to a decrease of US$0.3 million in staff costs. The year-over-year decrease was mainly due to a decrease of US$4.1 million in staff costs, a decrease of US$0.7 million in share-based compensation expenses, partially offset by an increase of US$3.7 million in research and development expenditure. Research and development expenses in the second quarter of 2026 also included share-based compensation expenses of US$0.6 million.

Sales and marketing expenses in the second quarter of 2026 were US$1.9 million, compared to US$1.2 million in the first quarter of 2026 and US$4.5 million in the same period of 2025. The sequential increase was mainly due to an increase of US$0.6 million in staff costs. The year-over-year decrease was mainly attributable to a decrease of US$2.3 million in staff costs. Sales and marketing expenses in the second quarter of 2026 also included share-based compensation expenses of US$29 thousand.

General and administrative expenses in the second quarter of 2026 were US$15.1 million, compared to US$15.0 million in the first quarter of 2026 and US$16.4 million in the same period of 2025. General and administrative expenses remained stable sequentially. The year-over-year decrease was mainly due to a decrease of US$1.8 million in professional service fees, a decrease of US$0.9 million in share-based compensation expenses, and a decrease of US$0.6 million in staff costs, partially offset by an increase of US$2.6 million in credit loss expense. General and administrative expenses in the second quarter of 2026 also included share-based compensation expenses of US$3.8 million.

Impairment on property, equipment and software in the second quarter of 2026 was US$9.2 million, compared to nil in the first quarter of 2026 and nil in the same period of 2025.

Loss from operations in the second quarter of 2026 was US$69.5 million, compared to US$54.3 million in the first quarter of 2026 and US$27.1 million in the same period of 2025.

Change in fair value of cryptocurrencyand Change in fair value of financial derivatives in the second quarter of 2026 were a loss of US$9.3 million and a loss of US$8.9 million, respectively, compared to a loss of US$24.9 million and a loss of US$16.0 million in the first quarter of 2026, and a gain of US$10.6 million and a gain of US$23.4 million in the second quarter of 2025, respectively. The losses were mainly due to the decreased bitcoin price on June 30, 2026, compared to the bitcoin price on March 31, 2026.

Foreign exchange gains (losses), net in the second quarter of 2026 were a loss of US$3.0 million, compared to a loss of US$4.0 million in the first quarter of 2026 and a gain of US$0.3 million in the same period of 2025, respectively.

Loss before income tax expense in the second quarter of 2026 was US$92.2 million, compared to US$88.8 million in the first quarter of 2026 and US$10.3 million in the same period of 2025.

Equity in gains (losses) of equity investees in the second quarter of 2026 was a loss of US$4.1 million, compared to a gain of US$0.2 million in the first quarter of 2026 and nil in the same period of 2025.

Net loss in the second quarter of 2026 was US$97.6 million, compared to US$88.7 million in the first quarter of 2026 and US$11.1 million in the same period of 2025.

Non-GAAP adjusted EBITDA in the second quarter of 2026 was a loss of US$74.9 million, as compared to a loss of US$76.3 million in the first quarter of 2026 and a gain of US$25.3 million in the same period of 2025. For further information, please refer to “Use of Non-GAAP Financial Measures” in this press release.

Foreign currency translation adjustment, net of nil tax, in the second quarter of 2026 was a gain of US$3.8 million, compared to a gain of US$5.2 million in the first quarter of 2026 and a gain of US$1.4 million in the same period of 2025, respectively.

Basic and diluted net loss per American depositary share (“ADS”) in the second quarter of 2026 was US$0.13. In comparison, basic and diluted net loss per ADS in the first quarter of 2026 was US$0.13, while basic and diluted net loss per ADS in the same period of 2025 were US$0.03. Each ADS represents 15 of the Company’s Class A ordinary shares.

As of June 30, 2026, the Company held Cryptocurrency assets with a fair value of US$47.0 million and Cryptocurrency receivable with an aggregate fair value of US$70.9 million, respectively. Cryptocurrency assets primarily consist of 698.5 bitcoins owned by the Company. Cryptocurrency receivable consists of 1,117.0 bitcoins pledged for secured term loans and 100.0 bitcoins transferred to a fixed-term product. The classification of cryptocurrency receivable as current assets is consistent with the corresponding secured term loans. As of June 30, 2026, the Company held a total of 1,915.5 bitcoins.

As of June 30, 2026, the Company had cash of US$66.0 million, compared to US$80.8 million as of December 31, 2025.

Accounts receivable, net as of June 30, 2026, were US$1.7 million, compared to US$19.3 million as of December 31, 2025. Accounts receivable were mainly due to an installment policy implemented for some major customers who meet certain conditions.

Investment in equity investees as of June 30, 2026, was US$11.8 million.

ADSs Outstanding

As of June 30, 2026, the Company had a total of 690,594,191 ADSs outstanding, each representing 15 of the Company’s Class A ordinary shares.

Recent Developments


Share Repurchase Program Using Portion of Digital Asset Treasury

On December 17, 2025, the Company announced that its board of directors had renewed a share repurchase program authorizing the repurchase of up to US$30 million of its outstanding ADSs or Class A ordinary shares over a 12-month period beginning December 12, 2025 (the “Share Repurchase Program”). Repurchases may be made through open-market transactions, privately negotiated transactions, block trades, or a combination thereof, subject to market conditions and regulatory requirements.

On August 4, 2026, the Company announced that it had been authorized to monetize a portion of its digital asset treasury to fund repurchases under the Share Repurchase Program, reflecting a disciplined capital allocation approach that balances active treasury management with the Company’s long-term commitment to maintaining a strategic digital asset treasury.

In late August, the Company sold 3,952 ETH and 54 Bitcoins, generating approximately US$13.9 million in cash, a portion of which was used for share repurchases. The Company repurchased approximately 2.8 million ADSs for about US$2.0 million in the first half of 2026 and an additional 13.6 million ADSs for approximately US$5.4 million in late August.

As of September 8, 2026, the Company had repurchased approximately 16.4 million ADSs for a total consideration of US$7.4 million under the Share Repurchase Program.

The sale of a portion of the Company’s digital assets does not represent a change in its long-term digital asset strategy.


At-the-Market Offering (“ATM”) Program

On October 24, 2025, the Company established a new ATM equity offering program to replace the prior program, which had expired. The renewal was intended to broaden banking relationships and enhance financial flexibility for future growth initiatives.

The Company has not made any sales under the ATM Program since the beginning of the second quarter of 2026 to date.

Business Outlook

For the third quarter of 2026, the Company expects total revenues to be in the range of US$11 million to US$15 million, reflecting the near-term market conditions and evolving customer dynamics, which are subject to change.

The Company will continue to closely monitor the global policy environment and market developments, and may revise or update its outlook as appropriate, based on future clarity and business visibility.

Conference Call Information

The Company’s management team will hold a conference call at 8:00 A.M. U.S. Eastern Time on September 8, 2026 (or 8:00 P.M. Singapore Time on the same day) to discuss the financial results. Details for the conference call are as follows:

Event Title:

Canaan Inc. Second Quarter 2026 Earnings Conference Call

Registration Link:


https://register-conf.media-server.com/register/BI95b35b81eafb40488eff6d3e49635cc0

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers and a unique access PIN, which can be used to join the conference call.

A live and archived webcast of the conference call will be available at the Company’s investor relations website at investor.canaan-creative.com.

About Canaan Inc.

Established in 2013, Canaan Inc. (NASDAQ: CAN), is a technology company focusing on ASIC high-performance computing chip design, chip research and development, computing equipment production, and software services. Canaan has extensive experience in chip design and streamlined production in the ASIC field. In 2013, Canaan’s founding team shipped to its customers the world’s first batch of mining machines incorporating ASIC technology under the brand name Avalon. In 2019, Canaan completed its initial public offering on the Nasdaq Global Market. To learn more about Canaan, please visit https://www.canaan.io/.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as Canaan Inc.’s strategic and operational plans, contain forward-looking statements. Canaan Inc. may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”) on Forms 20-F and 6-K, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Canaan Inc.’s beliefs and expectations, such as expectations with regard to revenue or mining hash rate deployment, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, the ability of the Company to execute against its goals, financial condition and results of operations; the expected growth of the bitcoin industry and the price of bitcoin; the Company’s expectations regarding demand for and market acceptance of its products, especially its bitcoin mining machines; the Company’s expectations regarding maintaining and strengthening its relationships with production partners and customers; the Company’s investment plans and strategies, fluctuations in the Company’s quarterly operating results; competition in its industry; changing macroeconomic and geopolitical conditions, including evolving international trade policies and the implementation of increased tariffs, import restrictions, and retaliatory trade actions; and relevant government policies and regulations relating to the Company and cryptocurrency. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Canaan Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Use of Non-GAAP Financial Measures

In evaluating Canaan’s business, the Company uses non-GAAP measures, such as adjusted EBITDA, as supplemental measures to review and assess its operating performance. The Company defines adjusted EBITDA as net loss excluding income tax (benefit) expenses, interest income, interest expense, depreciation and amortization expenses, share-based compensation expenses, impairment on property, equipment and software, change in fair value of financial instruments other than derivatives and excess of fair value of convertible preferred shares. The Company believes that the non-GAAP financial measures provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools and investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP. One of the key limitations of using adjusted EBITDA is that it does not reflect all of the items of income and expense that affect the Company’s operations. Further, the non-GAAP financial measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.

Investor Relations Contact

Canaan Inc.
Xi Zhang
Email: [email protected]

Christensen Advisory
Christian Arnell
Email: [email protected]

Media Contact

BlocksBridge Consulting
Jesse Colzani
Email: [email protected]

 


CANAAN INC.


UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


(all amounts in thousands, except share and per share data, or as otherwise noted)


As of December 31,


As of June 30,


2025


2026


USD


USD


ASSETS


Current assets:

Cash

80,778

66,006

Accounts receivable, net

19,290

1,725

Inventories

180,816

128,835

Prepayments and other current assets

99,243

83,134

Cryptocurrency receivable, current

52,699

29,139

Held-for-sale assets, current

464

1,713


Total current assets

433,290

310,552


Non-current assets:

Cryptocurrency

83,339

47,019

Cryptocurrency receivable, non-current

35,133

41,786

Investment in equity investees

11,790

Property, equipment and software, net

44,028

27,388

Intangible asset

689

583

Operating lease right-of-use assets

2,880

2,090

Deferred tax assets

191

197

Other non-current assets

489

3,835

Non-current financial investment

2,845

1,000


Total non-current assets

169,594

135,688


Total assets

602,884

446,240


LIABILITIES, AND SHAREHOLDERS’
EQUITY


Current liabilities

Current portion of long-term loans

28,515

23,888

Accounts payable

25,600

15,455

Contract liabilities

9,317

4,107

Income tax payable

11,403

11,832

Accrued liabilities and other current
liabilities

54,548

51,986

Operating lease liabilities, current

1,706

1,228


Total current liabilities

131,089

108,496


Non-current liabilities:

Long-term loans

23,731

34,901

Operating lease liabilities, non-current

948

481

Deferred tax liability

117

99

Other non-current liabilities

9,631

9,557


Total liabilities

165,516

153,534


Shareholders’ equity:

Class A Ordinary shares (US$0.00000005
par value; 999,643,050,556 authorized,
10,431,482,973 and 11,237,922,873 shares
issued, 9,703,445,043 and 10,557,490,218
shares outstanding as of December 31, 2025
and June 30, 2026, respectively)

1

1

Class B Ordinary shares (US$0.00000005
par value; 356,624,444 shares authorized,
311,624,444 shares issued and outstanding
as of December 31, 2025 and June 30, 2026)

Treasury stocks (US$0.00000005 par value;
366,981,615 and 342,319,770 shares as of
December 31, 2025 and June 30, 2026,
respectively)

(37,172)

(20,255)

Additional paid-in capital

1,177,057

1,192,812

Statutory reserves

14,892

14,892

Accumulated other comprehensive loss

(56,653)

(47,632)

Accumulated deficit

(660,757)

(847,112)


Total shareholders’ equity

437,368

292,706


Total liabilities and shareholders’ equity

602,884

446,240

 


CANAAN INC.


UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS


(all amounts in thousands of USD, except share and per share data, or as otherwise noted)


For the Three Months Ended


June 30,

2025


March 31,

2026


June 30,

2026


USD


USD


USD


Revenues

Products revenue

71,923

42,863

13,630

Mining revenue

28,072

19,124

17,657

Other revenues

214

706

575


Total revenues


100,209


62,693


31,862


Cost of revenues

Product cost

(58,759)

(62,365)

(40,277)

Mining cost

(31,995)

(22,677)

(20,388)

Other cost

(149)

(557)

(530)


Total cost of revenues


(90,903)


(85,599)


(61,195)


Gross profit (loss)


9,306


(22,906)


(29,333)


Operating expenses:

Research and development expenses

(16,406)

(15,390)

(14,865)

Sales and marketing expenses

(4,472)

(1,195)

(1,909)

General and administrative expenses

(16,361)

(15,020)

(15,080)

Impairment on property and
equipment

(9,220)

Gain on disposal of property,
equipment and software

863

197

950


Total operating expenses


(36,376)


(31,408)


(40,124)


Loss from operations


(27,070)


(54,314)


(69,457)

Interest expense, net

(309)

(779)

(492)

Change in fair value of
cryptocurrency

10,576

(24,913)

(9,298)

Change in fair value of financial
instruments other than derivatives

(17,485)

Change in fair value of financial
derivatives

23,440

(15,974)

(8,908)

Foreign exchange gains (losses), net

338

(3,997)

(3,040)

Other income (loss), net

225

11,198

(1,002)


Loss before income tax expenses


(10,285)


(88,779)


(92,197)

Income tax expense

(773)

(190)

(1,263)

Equity in gains (losses) of equity
investees

221

(4,147)


Net loss


(11,058)


(88,748)


(97,607)

Foreign currency translation
adjustment, net of nil tax

1,376

5,182

3,839


Total comprehensive loss


(9,682)


(83,566)


(93,768)


Weighted average number of shares
used in per share calculation:

— Basic

5,994,860,758

10,371,318,890

10,847,269,108

— Diluted

5,994,860,758

10,371,318,890

10,847,269,108


Net loss per share (cent per share)

— Basic

(0.18)

(0.86)

(0.90)

— Diluted

(0.18)

(0.86)

(0.90)


Share-based compensation expenses

 were included in:

Cost of revenues

80

89

86

Research and development expenses

1,363

668

620

Sales and marketing expenses

59

43

29

General and administrative expenses

4,670

3,815

3,808

 

The table below sets forth a reconciliation of net loss to non-GAAP adjusted EBITDA for the period indicated:


For the Three Months Ended


June 30,

2025


March 31,

2026


June 30,

2026


USD


USD


USD


Net loss


(11,058)


(88,748)


(97,607)

Income tax expense

773

190

1,263

Interest expense, net

309

779

492


EBIT


(9,976)


(87,779)


(95,852)

Depreciation and amortization expenses

11,657

6,816

7,193


EBITDA


1,681


(80,963)


(88,659)

Share-based compensation expenses

6,172

4,615

4,543

Impairment on property, equipment and
software

9,220

Change in fair value of financial
instruments other than derivatives

17,485


Non-GAAP adjusted EBITDA


25,338


(76,348)


(74,896)

 

Cision View original content:https://www.prnewswire.com/news-releases/canaan-inc-reports-unaudited-second-quarter-2026-financial-results-302872107.html

SOURCE Canaan Inc.

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

PR Newswire

New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide

IRVING, Texas, Sept. 8, 2026 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, “Math,” featuring the iconic, award-winning actor, producer and director, Kevin Costner. The partnership is designed to raise awareness of the critical importance of early cancer detection and introduce a national audience to Caris Detect™, Caris’ groundbreaking multi-cancer early detection (MCED) blood test.

Caris Life Sciences Logo

At the heart of the “Math” campaign is a simple but powerful promise: when cancer is found earlier, patients may have more treatment options and better outcomes. Caris Detect is designed to help individuals gain earlier insight into their health through advanced blood-based testing powered by molecular science and artificial intelligence. By providing information that may help identify cancer-associated signals before symptoms appear, Caris Detect empowers people to take a more proactive role in their healthcare.

Caris Detect is a multi-cancer early detection blood test designed to identify cancer-associated molecular signals in the bloodstream. The test combines ultra-deep Whole Genome Sequencing (WGS), Whole Transcriptome Sequencing (WTS), and advanced artificial intelligence to analyze a broad range of biological signals associated with cancer. Caris Detect analyzes the entire genome and transcriptome to provide a more comprehensive view of molecular patterns associated with cancer compared to approaches that evaluate only a limited subset of biomarkers.

“Early detection remains one of the greatest opportunities to save lives-,” said David Dean Halbert, Founder, Chairman and Chief Executive Officer of Caris Life Sciences. “With Caris Detect, we are applying decades of leadership in molecular science and artificial intelligence to help create a future where cancer may be detected earlier, when treatment options are broader and survival rates are improved. Kevin’s authenticity, credibility, and ability to connect with people across generations will inspire more people to take a proactive approach to their health.”

Costner partnered with Caris because of the company’s mission to transform healthcare through earlier detection and advanced molecular science. The campaign highlights a simple belief: when people have access to better information earlier, they can make more informed healthcare decisions.

“Cancer has touched so many families, including people I know and care about,” said Kevin Costner, award-winning actor, director and producer. “What attracted me to a partnership with Caris was their commitment to helping people get information earlier and its belief that science and technology can help change what’s possible. If a conversation about early detection encourages even one person to become more proactive about their health, that’s meaningful. Get the test.”

Individuals interested in learning more about Caris Detect may visit CarisDetect.com.

About Caris Detect™

Caris Detect™ is a multi-cancer early detection blood test designed to identify cancer-associated molecular signals using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced artificial intelligence. The test analyzes a broad range of molecular information to help support earlier detection and more informed healthcare conversations. Caris Detect is designed to complement routine cancer screening and is now available nationwide.

About Caris Life Sciences 
Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,” “contemplate,” “believe,” “estimate,” “predict,” or “continue” or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; continued development, performance and commercialization of Caris Detect; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:
Corporate Communications
[email protected]
214.294.5606 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-launches-new-national-commercial-featuring-kevin-costner-to-raise-awareness-of-early-cancer-detection-and-caris-detect-302870457.html

SOURCE Caris Life Sciences

Nova Minerals’ Marches towards Antimony Production with Arrival of Processing & Refining Equipment in Alaska

Anchorage, Alaska, Sept. 08, 2026 (GLOBE NEWSWIRE) — Nova Minerals Corp (“Nova Minerals” or the “Company”) (NYSE American: NVA | ASX: NVA) is pleased to report the arrival of approximately 500 tons of equipment in Port MacKenzie, Alaska, to enable the construction of its planned antimony processing and refining facility.

This marks a significant milestone in the Company’s efforts to establish a fully secured and integrated domestic supply chain for antimony, funded by a US$43.4 million award from the Department of War under Title III of the Defense Production Act.

The shipment included more than 40 containers and multiple oversized loads carrying crushing, ore sorting, milling, flotation and refining equipment. The barge departed Seattle on August 26, arriving in Cook Inlet on September 6.

A time lapse video of Nova’s antimony processing plant equipment being unloaded at Port MacKenzie can be viewed at the link below.

The delivery of this critical processing equipment represents the culmination of six months of detailed procurement, consolidation, planning and logistics coordination undertaken by the Nova Minerals team. The delivery has advanced Nova Minerals’ antimony strategy ahead of schedule, supporting its plans to develop a processing and refining facility in Alaska with production targeted for 2027.

Nova Minerals CEO, Mr. Christopher Gerteisen, commented:

“The shipment arrived ahead of schedule, which will enable us to get construction underway at speed. By acquiring and transporting modern processing and milling equipment from a recently decommissioned site in North America, rather than starting from scratch, we’ve been able to significantly accelerate the path to construction, and ultimately, the production of antimony. This approach has also delivered meaningful capital cost savings.

“Antimony is one of the critical minerals recognized by the Department of War as a priority for the United States. It has essential applications in defense, energy storage, and advanced electronics, which is why this project is so important to our national and economic security.

“We’re proud to embark on the next phase of development and the construction of the antimony processing facility.”

U.S. Congressman Nick Begich praised the effort, stating, “The arrival of nearly 500 tons of infrastructure and refining equipment at Port MacKenzie marks an important first step toward refining antimony in the Mat-Su Valley and building a secure, fully domestic supply chain right here in Alaska,” said Congressman Begich.

“I applaud the Department of War for recognizing the national security importance of this effort and investing in American production,” he said.

“This is exactly the kind of project we need: Alaska resources, Alaska workers, and American production strengthening our national security.”

Alaska State Rep. Kevin McCabe, whose district includes the areas where Nova Minerals will be operating, was delighted by the landmark occasion. “I could not be more excited to finally see this movement on the part of Nova Minerals,” said Rep. McCabe.

I have watched this project develop, have flown to the Estelle area, and I know how many jobs this will create and the stimulus it will provide to the Alaska economy. This is a fabulous stage of development, and Nova’s use of Port MacKenzie demonstrates their commitment to the Valley and Alaska.”

The Port MacKenzie processing facility is designed to process stibnite-bearing material and, initially, produce antimony trisulfide as part of the U.S. Department of War project. The modular design of the facility provides flexibility to scale operations over time and potentially expand into the production of additional saleable refined antimony products, including antimony metal and antimony trioxide. This flexibility is intended to allow Nova Minerals to respond to evolving market requirements while building an integrated domestic processing capability in the United States.

The Port MacKenzie district provides a strategic location for the Company’s development of a critical minerals refinery. It affords access to a year-round deepwater port, Alaska’s road and highway system, the West Susitna Access Road, and the Port MacKenzie rail spur that will connect to the Alaska Railroad mainline. These infrastructure advantages are expected to support the movement of materials and products as the project advances toward production.

Mat-Su Borough Mayor Edna DeVries noted the benefits of the project for the region and its residents. “For some time, the Mat-Su Borough invested in the infrastructure necessary to position Port MacKenzie as an Alaskan industrial center. Seeing refining and processing equipment arrive at the port is evidence that those investments are paying off,” she remarked.

This project represents more than a shipment of equipment. It represents jobs, economic diversification, value-added resource development, and a stronger future for Alaska”, said Mayor DeVries.




Figure 1.

Barge loaded with Nova’s antimony processing equipment arriving at Port MacKenzie


Figure 2.

Barge unloading at Port MacKenzie


Figure 3.

40ft shipping containers loaded onto trucks for the short haul to the Nova Minerals antimony processing plant site


Figure 4.

Aerial view of Nova Minerals antimony processing plant site which has been prepared ready for construction


Figure 5.

Aerial view of Port MacKenzie highlighting the site for Nova’s antimony processing plant

About Nova Minerals Corp

Nova Minerals Corp is advancing one of the world’s largest undeveloped gold deposits into production and securing a U.S. domestic supply of the critical mineral antimony. The Company is focused on the exploration and development of the Estelle Gold and Critical Minerals Project, located in Alaska, a tier-one mining jurisdiction.

Estelle hosts two defined multi-million-ounce gold resources, and more than 20 prospects distributed along a 35-kilometre mineralized trend, in the prolific Tintina Gold Belt, a province which hosts a >220 million ounce (Moz) documented gold endowment and some of the world’s largest gold mines and discoveries, including Kinross Gold Corporation’s Fort Knox Gold Mine. In parallel, Nova is advancing its critical minerals strategy, fully-funded by a US$43.4 million U.S. Department of War award to develop a domestic antimony supply chain, targeted for production in 2027.

Further discussion and analysis of the Estelle Project is available through the interactive Vrify 3D animations, presentations, and videos, all available on the Company’s website www.novamineralscorp.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical fact, contained in this press release are forward-looking statements and that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nova Minerals Corp’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and Nova Minerals Corp undertakes no duty to update such information except as required under applicable law.

For further information:

Nova Minerals: Media: Investor Relations:
Craig Bentley Jenna Shinderman Dave Gentry, CEO
Executive Director Sodali & Co RedChip Companies, Inc.
Ph: 1-720-550-4223 Ph: 1-631-918-4047 Ph: 1-407-644-4256
E: [email protected] E: [email protected] E: [email protected]

Attachments



FTC Solar to Participate in Upcoming Investor Events

AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) — FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, software and engineering services, announced today that members of its management team are scheduled to participate in meetings with investors at the following upcoming conferences and events:

H.C. Wainwright Global Investment Conference – September 15, 2026, New York. The company will host in-person investor meetings. Interested investors should contact their H.C. Wainwright sales representative.

TD Cowen Energy Conference – September 24, 2026, Austin. The company will host in-person investor meetings. Interested investors should contact their TD Cowen sales representative.

About FTC Solar Inc.

Founded in 2017 by a group of renewable energy industry veterans, FTC Solar is a global provider of solar tracker systems, technology, software, and engineering services. Solar trackers significantly increase energy production at solar power installations by dynamically optimizing solar panel orientation to the sun. FTC Solar’s innovative tracker designs provide compelling performance and reliability, with an industry-leading installation cost-per-watt advantage.

FTC Solar Investor Contact:

Bill Michalek 
Vice President, Investor Relations 
FTC Solar
T: (737) 241-8618 
E: [email protected]



Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels

ACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and Lovell Government Services, Inc. (“Lovell”), a Service-Disabled Veteran-Owned Company (“SDVOSB”) specializing in federal healthcare distribution, today announced a distribution, co-marketing and strategic partnership designed to support the introduction of Bluejay’s products into the U.S. federal healthcare market following applicable U.S. Food and Drug Administration (“FDA”) clearance or other required regulatory authorization.

The partnership is designed to establish a scalable federal market access and procurement infrastructure in advance of potential commercialization, positioning Bluejay to efficiently pursue opportunities across some of the largest government-operated healthcare systems in the United States, subject to applicable FDA clearance or other required regulatory authorization for its products.

Under the agreement, Lovell will serve as Bluejay’s exclusive distributor for federal procurement opportunities requiring or favoring SDVOSB set-aside and preferred status, including opportunities within the U.S. Department of Veterans Affairs (“VA”), Department of Defense (“DoD”), Military Health Systems (“MHS”) and Indian Health Service (“IHS”). Lovell will also have non-exclusive rights to participate in open-market federal, state and local government procurement opportunities.

Strategic Access to a Large Federal Healthcare Market

The partnership provides Bluejay with a strategic framework to access and pursue opportunities across the significant U.S. federal healthcare market, creating a potential pathway for commercial expansion if and when its devices receive applicable FDA clearance or approval and are commercially launched in the United States.

The Veterans Health Administration (“VHA”), the largest integrated healthcare system in the United States, encompasses approximately 170 major medical centers and 1,193 outpatient clinics, with a proposed FY2026 budget of approximately $165.1 billion. The broader federal healthcare opportunity includes approximately 45 U.S. military hospitals and 572 military medical clinics within the DoD healthcare system, with the Defense Health Agency (“DHA”) having a proposed FY2026 budget of approximately $64 billion. The Indian Health Service (“IHS”), with a proposed FY2026 budget of approximately $8.1 billion, serves approximately 2.8 million American Indians and Alaska Natives through approximately 170 IHS and tribally managed service units.

Together, these federal healthcare systems represent an extensive network of hospitals, medical centers, outpatient clinics and other care settings in which timely access to clinically relevant information may be important.

“We believe this partnership represents an important step in building Bluejay’s commercial infrastructure well ahead of potentially marketing medical devices in the US.” said Neil Dey, Chief Executive Officer of Bluejay Diagnostics. “The scale of the federal healthcare system is significant, and establishing a pathway into these markets could provide Bluejay with an important future commercialization channel.”

Dey continued, “We believe regulatory, manufacturing and commercial readiness should advance in parallel. Lovell brings established federal contracting infrastructure, SDVOSB capabilities and experience navigating government procurement pathways that would be difficult and time-consuming for Bluejay to develop independently.”

Lovell Brings Established Federal Market Infrastructure

Lovell Government Services specializes in helping medical and healthcare companies navigate the U.S. federal marketplace. Its experience includes working with VA medical centers, military hospitals and clinics, IHS facilities and other federal healthcare organizations.

Through the partnership, Lovell will leverage its SDVOSB status, federal contracting capabilities and industry relationships to support market development, facilitate appropriate introductions and pursue federal procurement opportunities for Bluejay. The parties may also collaborate on educational initiatives, conferences, customer engagement and other federal market-development activities.

Lovell’s established federal procurement infrastructure includes access to contract vehicles such as the VA Federal Supply Schedule (“FSS”), GSA Advantage, GSA Multiple Award Schedule (“MAS”), Defense Logistics Agency (“DLA”) DAPA and Electronic Catalog (“ECAT”). ECAT is a preferred DoD procurement vehicle for medical supplies and devices and is also utilized by the VA and IHS.

Lovell also participates in the Association of Military Surgeons of the United States (“AMSUS”), providing potential exposure to more than 8,000 federal health professionals through publications, meetings and conferences.

“We are proud to partner with Bluejay Diagnostics as they prepare to bring the Symphony platform to market. At Lovell, our mission is to connect innovative healthcare technologies with the federal healthcare providers serving our Veterans, active-duty service members, and their families. By establishing the necessary contracting and procurement pathways now, we can help position Bluejay to efficiently reach these critical healthcare systems following applicable FDA clearance,” said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.

Building Commercial Readiness in Parallel With Regulatory Development

The partnership reflects Bluejay’s broader strategy of building commercialization capabilities while advancing its clinical, regulatory and manufacturing programs. Bluejay and Lovell may jointly pursue federal market-development initiatives and engage appropriate healthcare, clinical, innovation and procurement stakeholders in preparation for potential future commercialization.

Note: The Company’s Symphony™ rapid diagnostic platform is an investigational device and is limited by United States law to investigational use.

About the SYMON Clinical Study Program:

The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to the FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.


About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

About Lovell Government Services

Lovell Government Services has been a trusted Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor since 2013 with a proven track record of helping suppliers successfully navigate the federal marketplace. As a five-time Inc. 5000 honoree, Lovell partners with medical, dental, pharmaceutical, and healthcare technology companies to expand access to federal healthcare systems while helping agencies streamline procurement and improve patient care for Veterans, military personnel, and other federal beneficiaries.

Learn more at www.lovellgov.com

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, “Risk Factors” in its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026 and June 30, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.

Investor Contact:

Neil Dey
Bluejay Diagnostics, Inc.
[email protected] 
Website: www.bluejaydx.com 

Lovell Government Services Contact:

Jeff McKay Lovell Government Services
[email protected] 
850-912-4680



Fifth Third Completes Comerica Technology and Brand Conversion

Fifth Third Completes Comerica Technology and Brand Conversion

Comerica customers now have full access to Fifth Third’s products, technology and services

CINCINNATI–(BUSINESS WIRE)–
Fifth Third Bancorp (NYSE: FITB) today announced it has completed the technical conversion of approximately 600,000 customers’ accounts and 293 banking centers across Arizona, California, Florida, Michigan and Texas from the Comerica franchise. Executed over Labor Day weekend, the conversion brings Comerica consumer and commercial customers onto Fifth Third’s platforms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908193975/en/

Today’s milestone completes the integration that began when the two companies merged on February 1, 2026. The combined company is now the ninth-largest U.S. bank with more than $300 billion in assets, operations in 17 of the 20 fastest-growing large U.S. metropolitan areas, and a retail footprint that reaches more than half of the U.S. population.

With the companies now operating on a single platform and under a single brand, Comerica customers gain access to Fifth Third’s full suite of consumer, commercial, payments, and wealth capabilities, including the award-winning Momentum® Banking suite and mobile app with features such as Early Pay and Extra Time®. These offerings are backed by a resilient balance sheet and an expansive network of approximately 1,500 branches and 21,300 ATMs. For customers, the change means new products and broader services delivered by the same local bankers and relationship teams they know.

“The power of this merger comes from what we can accomplish together as one team,” said Tim Spence, chairman, CEO and president of Fifth Third. “Now that we’re on one platform, we can bring the full strength of the combined company to every client, in every market we serve. Our teams planned, trained and tested for this moment, and they delivered a disciplined conversion this weekend. We’re continuing to monitor the customer experience closely and are ready to help wherever needed.”

With the conversion complete, Fifth Third is positioned to build on its market leadership in the Midwest while continuing to invest in high-growth markets across Texas, the Southeast, Arizona and California.

  • In Michigan, Fifth Third holds the No. 1 retail deposit share statewide and in Detroit. Following conversion, Comerica customers will gain 60% more branch access, while existing Fifth Third customers gain 42% more access.

  • In Texas, Fifth Third now operates 107 financial centers and plans to invest nearly $1 billion over the next five years, including opening 150 new financial centers by 2029 to strengthen its position in one of the nation’s fastest-growing economic markets.

  • Across former Comerica markets, Fifth Third expects household growth to accelerate as the full suite of products, digital capabilities and analytically driven direct marketing are introduced to new markets.

  • By 2030, Fifth Third expects to operate approximately 1,750 branches, with more than half of the network located in high-growth markets across Texas, the Southeast, Arizona and California.

For additional information on what customers can expect, visit 53.com/BetterTogether.

About Fifth Third

Fifth Third is a bank that’s as long on innovation as it is on history. Since 1858, we’ve been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it’s one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere’s World’s Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is to be the one bank people most value and trust.

Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank, and its common stock is traded on the New York Stock Exchange under the symbol “FITB.” Investor information and press releases can be viewed at www.53.com. Deposit and credit products provided by Fifth Third Bank, National Association. Member FDIC.

Forward-Looking Statement

This communication contains statements that constitute “forward-looking statements” within the meaning of, and subject to the protections of, Section 27A of the Securities Act, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “believe,” “deliver,” “expect,” “may,” “should,” “will,” “would,” and other similar words and expressions or the negative of such terms or other comparable terminology. Such forward-looking statements include, but are not limited to, statements about the integration of Comerica, including the risk that anticipated benefits from the transaction may not be fully realized or may take longer than anticipated to be realized, the risk that Fifth Third may be unable to successfully execute its business plans and strategies and manage the risks involved in the acquisition and integration of Comerica. No assurances can be given that the forward-looking statements contained in this communication will occur as expected and actual results may differ materially from those included in this communication. Any forward-looking statement made in this communication is based solely on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except to the extent required by law. These and other important factors, including those discussed under “Risk Factors” in Fifth Third Bancorp’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as Fifth Third’s subsequent filings with the SEC, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements herein are made only as of the date they were first issued, and unless otherwise required by applicable securities laws, Fifth Third disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Category: Other

Jennifer Hendricks Sullivan (Media Relations)

[email protected]

Matt Curoe (Investor Relations)

[email protected] | 513-534-2345

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Software Finance Asset Management Banking Data Management Professional Services Technology Digital Cash Management/Digital Assets

MEDIA:

Carter’s Introduces Not-So-Scary Monsters to Help Make Bedtime Easier and More Fun for Families

Carter’s Introduces Not-So-Scary Monsters to Help Make Bedtime Easier and More Fun for Families

New collection combines 161 years of Carter’s sleepwear expertise with an interactive Monster Room Scanner and expert-backed sleep guidance

Key Facts

  • Nearly 70% of parents of children ages 2–6 say their child’s bedtime routine is at least somewhat stressful, according to new Carter’s research.

  • Carter’s Not-So-Scary Monsters collection brings playful monster characters to sleepwear and playwear for babies through big kids, starting at $7.

  • A new Monster Room Scanner in the Carter’s app turns the familiar “check for monsters” bedtime ritual into an interactive experience featuring the Not-So-Scary Monsters.

  • Carter’s Official Sleep Consultant Dr. Funke Afolabi-Brown, a triple board-certified sleep physician and pediatric sleep expert, is providing expert-backed guidance to help families navigate bedtime.

  • The collection is available at Carter’s stores and online.

ATLANTA–(BUSINESS WIRE)–
Bedtime isn’t always the peaceful wind-down parents hope for. Nearly 70% of parents of children 2 to 6 years old say their child’s bedtime routine is at least somewhat stressful, according to new Carter’s research. From getting ready for bed and turning out the lights to staying in bed and falling asleep, parents say challenges can show up throughout the nightly routine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908117365/en/

A child laughs wearing the DreamPlush Footed Pajama from Carter's latest Not-So-Scary Monsters collection.

A child laughs wearing the DreamPlush Footed Pajama from Carter’s latest Not-So-Scary Monsters collection.

In their effort to “make bedtime the best time” Carter’s is launching Not-So-Scary Monsters, a new sleepwear collection introducing families to some friendly helpers as they wind down for the night.

With the guidance of Carter’s Official Sleep Consultant, Dr. Funke Afolabi-Brown, and a cast of playful monster characters, the brand pairs trusted sleep expertise with imaginative play to help families navigate everything from brushing teeth to sweet dreams.

Each Not-So-Scary Monster has a job to do. Miss Squigz helps kids get out that last burst of energy before winding down, while six-legged Skooter knows a thing or two about getting wiggly kids into pajamas. Bartholomew Theodore Thornhill III is the resident hygiene hero, and twins Carrot and Cake help kids remember which bedtime steps come next.

The new pals even lend a hand with one of the most tried-and-true bedtime rituals: checking under the bed for monsters. A new Monster Room Scanner in the Carter’s app lets kids, with a parent’s permission, scan their bedroom for “scary monsters,” only to discover their friendly Not-So-Scary Monster bedtime buddies instead.

“For generations, families have trusted Carter’s to get their little ones cozy and ready for bed, but we know pajamas are just one part of the nightly routine,” said Sarah Crockett, Chief Marketing Officer at Carter’s. “Not-So-Scary Monsters lets us show up for more of those moments, giving kids something to look forward to at bedtime and parents a little more support along the way.”

As Carter’s Official Sleep Consultant for this campaign, Dr. Funke Afolabi-Brown, MD, a triple-board-certified sleep medicine physician and nationally recognized pediatric sleep expert, will provide practical guidance around children’s sleep, bedtime routines, and nighttime anxiety.

“For young children, a predictable bedtime routine can provide important cues that it’s time to slow down and prepare for sleep,” said Dr. Brown. “The goal doesn’t have to be a perfect bedtime routine. Simple, consistent steps, paired with a little play and imagination, can help kids feel more engaged in the process and make the transition to sleep feel more manageable for the whole family.”

TheNot-So-Scary Monsters collection features sleepwear and playwear in Carter’s signature styles and fabrics, with looks for every stage from baby to big kid. Pricing starts at $7 for baby and goes up to $28 for kids.

The Not-So-Scary Monsters collection and the best of Carter’s PJs are available starting September 10 at Carter’s stores and online at carters.com.

Survey Methodology

The survey was conducted among 504 parents of children 2 to 6 years old.

About Carter’s

Carter’s, Inc. is North America’s largest and most-enduring apparel company exclusively for babies and young children. The Company’s core brands are Carter’s and OshKosh B’gosh, iconic and among the sector’s most trusted names. These brands are sold through more than 1,000 Company-operated stores in the United States, Canada, and Mexico, and online at www.carters.com, www.oshkosh.com, www.cartersoshkosh.ca, and www.carters.com.mx. Carter’s also is the largest supplier of baby and young children’s apparel to North America’s biggest retailers. The Company’s Child of Mine brand is available exclusively at Walmart, its Just One You brand is available at Target, and its Simple Joys brand is available on Amazon.com. The Company’s emerging brands include Little Planet, crafted with organic fabrics and sustainable materials, Otter Avenue, a toddler-focused apparel brand, and Skip Hop, baby essentials from tubs to toys. Carter’s is headquartered in Atlanta, Georgia. Additional information may be found at www.carters.com.

About Dr. Funke Afolabi-Brown

Dr. Funke Afolabi-Brown is a triple board-certified physician in Pediatrics, Pediatric Pulmonology, and Sleep Medicine and founder of The Restful Sleep Place, a family-centered sleep practice providing evidence-based care for children and adults. She completed her sleep medicine training at the University of Pennsylvania and previously served as faculty at Children’s Hospital of Philadelphia. A Fellow of the American Academy of Sleep Medicine, Dr. Brown is also the bestselling author of Beyond Tired: A Sleep Physician’s Guide to Solving Your Child’s Sleep Problems for Good and a nationally recognized speaker on pediatric sleep health as well as sleep for the entire family.

Alana Gardner

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Apps/Applications Technology Children Other Retail Baby/Maternity Specialty Family Fashion Consumer Retail

MEDIA:

Photo
Photo
A child laughs wearing the DreamPlush Footed Pajama from Carter’s latest Not-So-Scary Monsters collection.

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

  • Compass will debut Change the Tune in TRD, a new U.S. healthcare provider (HCP) education campaign for treatment-resistant depression (TRD) at Booth #901
  • Seven poster presentations include new health economics and outcomes research (HEOR) data alongside encore analyses from the COMP360 clinical development program

LONDON & NEW YORK–(BUSINESS WIRE)–
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress 2026, taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data examining the burden of TRD alongside encore presentations from its COMP360 psilocybin clinical development program.

Change the Tune in TRD: Advancing HCP Education

Change the Tune in TRD is a new educational initiative for U.S. HCPs exploring the neurobiology and navigating care pathways in TRD. The campaign will be debuted in a three-panel Innovation Theater on September 15th from 12:15-1:30pm in Room 220-222. The featured panelists include:

  • Saundra Jain MA, PsyD, LPC, Psychotherapist, Adjunct Clinical Affiliate, University of Texas at Austin School of Nursing; Private Practice, Austin, Texas

  • Bryan B. Shapiro MD MPH, Board-Certified Psychiatrist, Assistant Clinical Professor of Psychiatry, UC Irvine Medical Center

  • Sandhya Prashad, MD, Interventional Psychiatrist, Founder and medical director of Sandhya J. Prashad, MD, Houston Ketamine Therapeutics, and Houston TMS Therapeutics

New HEOR Data

  • Real-World Healthcare Costs and Resource Utilization Across Health States Among Patients with Treatment-Resistant Depression – presented by Yechu Hua, poster #186
  • Characterization of Depression Episodes to Inform Real-World Health States for Major Depressive Disorder and Treatment-Resistant Depression – presented by Vicki Wing, poster #88
  • Behavioral Health Provider Perspectives on Management of Individuals with TRD – presented by Caroline Hostetler, poster #95
  • Identifying Treatment-Resistant Depression in the Real-World: Clinical Practice and Barriers to Care – presented by Matthew Sidovar, poster #89

Encore COMP360 Presentations

  • Demographic and Clinical Characteristics of Participants Receiving COMP360 Psilocybin Treatment for Treatment-Resistant Depression Across Two Pivotal Phase 3 Trials –​ presented by Kevin Loh,poster #93
  • Durability of Efficacy and Safety of COMP360 Psilocybin for Treatment-resistant Depression Across 26 Weeks in a Double-blind, Randomised, Controlled Phase 3 Study​​ – presented by Collin Challis,poster #92

  • Efficacy and Safety of COMP360 Psilocybin for ​Treatment-resistant Depression (TRD) in Two Phase 3, ​Double-blind, Randomized, Controlled Studies – presented by Juliana Gassmann,poster #91

Additional Congress Activities

  • Disease State Booth: #901

    Medical Booth: #937​

About treatment resistant depression (TRD)

Depression, one of the most common mental health disorders, significantly impacts relationships, work performance, overall quality of life, and is associated with an increased risk of suicide. Major depressive disorder (MDD) has been ranked as the third cause of the burden of disease worldwide in 2008 by the World Health Organization (WHO), which has projected that this disease will rank first by 2030.

It is estimated that approximately 4 million patients in the U.S. with MDD live with TRD1. TRD is broadly defined as an inadequate response to two or more appropriate courses of approved medications. TRD has a significantly greater impact on individuals compared to MDD, leading to residual symptoms, poorer quality of life, increased comorbidities, higher mortality, and an increased risk of suicide compared to non-treatment resistant MDD.

About Compass Pathways

We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.

Compass is headquartered in London, UK, with a U.S. office in New York.

We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, statements regarding our business strategy and goals; our expectations regarding the safety or efficacy of our investigational COMP360 psilocybin treatment, including as a treatment for treatment of TRD; our plans and expectations regarding our clinical trials, including our phase 3 trials in TRD; any implication that preliminary results will be predictive of full safety and efficacy data from our phase 3 program; the potential for our current or any future clinical trials to support regulatory filings and approvals for COMP360 psilocybin treatment on an accelerated basis or at all; our ability to obtain regulatory approval and adequate coverage and reimbursement; our ability to transition from a clinical-stage to a commercial-stage organization and effectively launch a commercial product, if regulatory approval is obtained; our expectations regarding our commercial readiness, if regulatory approval is obtained; and our expectations regarding the benefits of our investigational COMP360 psilocybin treatment. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Compass’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results; our need for substantial additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our clinical trials; our efforts to obtain FDA approval, or approval from regulatory authorities in other jurisdictions, for our investigational COMP360 psilocybin treatment on an accelerated basis, or at all, may be unsuccessful; our efforts to commercialize and obtain coverage and reimbursement for our investigational COMP360 psilocybin treatment, if approved, may be unsuccessful; and those risks and uncertainties described under the heading “Risk Factors” in Compass’s most recent annual report on Form 10-K or quarterly report on Form 10-Q and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. Except as required by law, Compass disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Compass’s current expectations and speak only as of the date hereof.

1. Wing V, et al. Poster S97 Contemporary Estimate of the National Prevalence of Treatment-Resistant Depression in the United States. Presented at ADAA 2026.

Enquiries

Media: Dana Sultan-Rothman, [email protected]

Investors: Stephen Schultz, [email protected], +1 401 290 7324

KEYWORDS: New York North America United States Ireland United Kingdom Europe

INDUSTRY KEYWORDS: Research Mental Health FDA Clinical Trials Biotechnology General Health Pharmaceutical Health Science Other Science

MEDIA:

Logo
Logo